XML 52 R40.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Segment Reporting [Abstract] |
Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated | Net loss for our reportable segment is as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30, |
| 2026 |  | 2025 |  | 2026 |  | 2025 |
Total revenue | $ | 51,240 |  |  | $ | 26,425 |  |  | $ | 95,446 |  |  | $ | 42,942 |  |
Cost of sales | 298 |  |  | 136 |  |  | 536 |  |  | 194 |  |
Gross profit | 50,942 |  |  | 26,289 |  |  | 94,910 |  |  | 42,748 |  |
Operating expenses |  |  |  |  |  |  |  |
External research and development expense (including amounts with related parties) (1) | 10,424 |  |  | 8,552 |  |  | 30,506 |  |  | 14,063 |  |
Internal research and development expense (including amounts with related parties): (2) |  |  |  |  |  |  |  |
Personnel-related costs | 26,602 |  |  | 23,632 |  |  | 52,452 |  |  | 46,697 |  |
Equipment, depreciation, and facility costs | 13,410 |  |  | 13,111 |  |  | 26,998 |  |  | 26,303 |  |
Other research and development costs | 10,380 |  |  | 9,941 |  |  | 18,849 |  |  | 16,407 |  |
Total internal research and development expense | 50,392 |  |  | 46,684 |  |  | 98,299 |  |  | 89,407 |  |
Total research and development expense (including amounts with related parties) | 60,816 |  |  | 55,236 |  |  | 128,805 |  |  | 103,470 |  |
Selling, general and administrative (including amounts with related parties) | 51,823 |  |  | 42,338 |  |  | 97,593 |  |  | 74,992 |  |
Total operating expenses | 112,639 |  |  | 97,574 |  |  | 226,398 |  |  | 178,462 |  |
Loss from operations | (61,697) |  |  | (71,285) |  |  | (131,488) |  |  | (135,714) |  |
Other income (expense), net |  |  |  |  |  |  |  |
Interest and investment income, net | 3,155 |  |  | 1,153 |  |  | 5,469 |  |  | 2,040 |  |
Change in fair value of related-party convertible note | (95,964) |  |  | 1,169 |  |  | (332,589) |  |  | (41,413) |  |
Change in fair value of warrant liabilities | (44,190) |  |  | 3,889 |  |  | (339,603) |  |  | 3,441 |  |
Interest expense related to revenue interest liability | (17,192) |  |  | (13,405) |  |  | (31,063) |  |  | (26,939) |  |
Interest expense (including amounts with related parties) | (14,052) |  |  | (15,479) |  |  | (28,645) |  |  | (30,810) |  |
Change in fair value of derivative liabilities | (692) |  |  | 1,931 |  |  | 416 |  |  | 7,509 |  |
Other income (expense), net | 242 |  |  | (278) |  |  | (5,675) |  |  | (319) |  |
Total other expense, net | (168,693) |  |  | (21,020) |  |  | (731,690) |  |  | (86,491) |  |
Loss before income taxes and noncontrolling interests | (230,390) |  |  | (92,305) |  |  | (863,178) |  |  | (222,205) |  |
Income tax expense | — |  |  | (269) |  |  | (9) |  |  | (35) |  |
Net loss | (230,390) |  |  | (92,574) |  |  | (863,187) |  |  | (222,240) |  |
Net loss attributable to noncontrolling interests, net of tax | (12) |  |  | (19) |  |  | (27) |  |  | (39) |  |
Net loss attributable to ImmunityBio common stockholders | $ | (230,378) |  |  | $ | (92,555) |  |  | $ | (863,160) |  |  | $ | (222,201) |  |
_______________
(1) | Our external research and development expense supports our various preclinical and clinical programs.
(2) | Our internal research and development expense includes payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of our research and development activities.
Schedule of Revenue by Geographic Region | We generate a portion of our revenues from outside of the U.S. Information about our revenue by geographic region is as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2026 |  | 2025 |  | 2026 |  | 2025
U.S. | $ | 50,722 |  |  | $ | 26,425 |  |  | $ | 94,904 |  |  | $ | 42,942 |
Europe | 518 |  |  | — |  |  | 542 |  |  | — |
Total segment revenue | $ | 51,240 |  |  | $ | 26,425 |  |  | $ | 95,446 |  |  | $ | 42,942 |

X
- Definition Tabular disclosure of reconciliation of profit (loss) by reportable segment to consolidated profit (loss). Includes, but is not limited to, reconciliation of income (loss) before income tax expense (benefit) and after income tax if income tax is allocated to reportable segment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue attributed to country of domicile and foreign country from which revenue is derived if it is not provided as part of reportable segment information. Includes, but is not limited to, subtotal of geographical information about group of countries. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration